Cite

HARVARD Citation

    Wijting, I. et al. (2017). Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet. 4 (12), pp. e547-e554. [Online]. 
  
Back to record